

# CONDENSED CONSOLIDATED INCOME STATEMENT

For the six months ended 31 December 2006 — Unaudited

	Notes	Six months ended 31 December	
		2006 RMB'000	2005 RMB'000
Turnover	3	<b>1,696,583</b>	1,286,230
Cost of sales		<b>(565,818)</b>	(422,525)
Gross profit		<b>1,130,765</b>	863,705
Other revenues		<b>49,050</b>	71,822
(Loss)/Gain arising from changes in fair value less estimated point-of-sale costs of biological assets	11	<b>(77,869)</b>	18,831
Selling and distribution expenses		<b>(177,989)</b>	(128,283)
General and administrative expenses		<b>(119,601)</b>	(77,176)
Research expenses		<b>(28,638)</b>	(23,902)
Other operating expenses		<b>(63,936)</b>	(46,426)
Profit from operations		<b>711,782</b>	678,571
Finance costs	5(a)	<b>(72,631)</b>	(83,717)
Share of net profit of associates		<b>43,501</b>	20,401
Change in fair value of convertible bonds	19	<b>(101,504)</b>	—
Loss on deemed disposal of interest in associates		—	(33,881)
<b>Profit before income tax</b>	5	<b>581,148</b>	581,374
Income tax	6	<b>(160)</b>	(25)
<b>Profit for the period</b>		<b>580,988</b>	581,349
<b>Profit attributable to:</b>			
Equity shareholders of the Company		<b>581,445</b>	581,326
Minority interests		<b>(457)</b>	23
<b>Profit for the period</b>		<b>580,988</b>	581,349
<b>Dividends</b>	7	<b>268,834</b>	262,364
<b>Earnings per share for profit attributable to equity shareholders of the Company during the period</b>			
— Basic	8(a)	<b>RMB0.25</b>	RMB0.25
— Diluted	8(b)	<b>RMB0.24</b>	RMB0.24